GENE ONLINE|News &
Opinion
Blog

2023-03-20| Trials & Approvals

AbbVie Unveils Latest Data For Skyrizi In Difficult-To-Treat Psoriasis

by Joy Lin
Share To

AbbVie has revealed new 52-week data from a Phase 3b study showing the efficacy of Skyrizi (risankizumab) treatment in a difficult-to-treat patient population with plaque psoriasis. 

In moderate to severe cases of plaque psoriasis, Skyrizi, an interleukin-23 (IL-23) inhibitor, improved signs and symptoms where other treatments such as secukinumab or ixekizumab, both IL-17A inhibitors, were suboptimal. 

The data was presented at a research session during the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans, Louisiana.

Related Article: Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results

Skyrizi Improves Signs and Symptoms of Psoriasis

Psoriasis is a chronic inflammatory skin condition that can be seen as thick, scaly skin due to the rapid growth of skin cells. It affects roughly 7.5 million people in the US alone, with 80-90% having plaque psoriasis. 

Skyrizi selectively blocks IL-23, a cytokine involved in inflammation that is thought to be linked to immune-mediated diseases like psoriasis. The drug is part of a 2016 collaboration between Boehringer Ingelheim and AbbVie, which saw AbbVie make a $595 million upfront payment in exchange for the commercialization rights to Skyrizi. 

In the Phase 3b study which enrolled 252 participants who had been treated with secukinumab or ixekizumab for at least six months with suboptimal response, 56.3% of patients treated with Skyrizi achieved the primary endpoint of signs and symptoms of psoriasis at week 16. 

At week 52, 63% of patients achieved clear or almost clear skin, reaching a primary endpoint. 19.8% of patients achieved completely clear skin at week 16, which grew to 26.2% by week 52. 20.2% of patients reported no symptoms of pain, itching, redness, and burning at week 16, while 27.4% reported no symptoms at week 52. No new safety signals were seen in the analysis.

“The evidence presented at the AAD meeting underscores the important role of Skyrizi in helping patients in a difficult-to-treat population achieve skin clearance and a resolution of their burdensome psoriasis symptoms,” said Nicole Selenko-Gebauer, M.D., MBA, vice president, global medical affairs, AbbVie.

Besides psoriasis, Skyrizi is being investigated in Phase 3 trials in Crohn’s disease, ulcerative colitis, and psoriatic arthritis. It has been approved to treat moderate to severe Crohn’s disease and certain adults with moderate to severe plaque psoriasis. 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Dutch Pharmaceutical Watchdog Organization Sues Abbvie over Humira Pricing
2023-02-22
AbbVie and Genmab’s Joint Cancer Treatment Receives EMA Validation
2022-10-28
M&A
AbbVie Buys DJS Antibodies For $255 Million To Beef Up Immunology Portfolio
2022-10-21
LATEST
Should People Looking to Lose Weight Skip Sugar Substitutes?
2023-05-30
Advancing Next-Generation Cancer Metabolic Therapy by Targeting Critical Amino Acid Metabolic Pathways: An Interview with Brian A. Van Tine, MD, PhD
2023-05-26
Rona Therapeutics, Keymed Biosciences Team Up To Develop siRNA Drugs For Kidney Disease
2023-05-25
CDC Calls an End to J&J’s COVID-19 Vaccine in the U.S.
2023-05-25
A Close Look at the Evolution of ESG in Biopharma
2023-05-22
Scientists Identified Potential New Drugs to Combat Blindness
2023-05-21
FDA Approves Astellas’ Non-hormonal Menopause Treatment After Extended Review
2023-05-19
EVENT
2023-05-16
The 2nd International Healthcare Week
Hong Kong , China
2023-06-02
2023 ASCO annual meeting
Chicago, USA
2023-07-26
BIO Asia-Taiwan 2023
Taipei, Taiwan
2023-09-06
2023 Bio Asia Pacific
Bangkok, Thailand
Scroll to Top